Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.
2.

Spontaneous remission of adult acute lymphoblastic leukemia: a very rare event.

Purohit A, Aggarwal M, Kumar S, Seth T, Mishra P, Mahapatra M, Saxena R, Sharma R, Singh PK, Venkateshan S.

Indian J Hematol Blood Transfus. 2015 Mar;31(1):159-60. doi: 10.1007/s12288-014-0351-y. Epub 2014 Feb 18.

PMID:
25548467
3.

Study on the promotion of bacterial biofilm formation by a Salmonella conjugative plasmid and the underlying mechanism.

Liu Z, Que F, Liao L, Zhou M, You L, Zhao Q, Li Y, Niu H, Wu S, Huang R.

PLoS One. 2014 Oct 9;9(10):e109808. doi: 10.1371/journal.pone.0109808. eCollection 2014.

4.

The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies.

Krone B, Kölmel KF, Grange JM.

BMC Cancer. 2014 Aug 16;14:595. doi: 10.1186/1471-2407-14-595. Review.

5.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH.

J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. Review.

6.

Pathogen-driven cancers and emerging immune therapeutic strategies.

Vandeven N, Nghiem P.

Cancer Immunol Res. 2014 Jan;2(1):9-14. doi: 10.1158/2326-6066.CIR-13-0179. Review.

7.

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product.

Hozouri H, Norouzian D, Nafissi-Varcheh N, Aboofazeli R.

Iran J Pharm Res. 2014 Winter;13(Suppl):143-50.

8.

Bacteria and tumours: causative agents or opportunistic inhabitants?

Cummins J, Tangney M.

Infect Agent Cancer. 2013 Mar 28;8(1):11. doi: 10.1186/1750-9378-8-11.

9.

Advances in cancer immunotherapy.

Snook AE, Waldman SA.

Discov Med. 2013 Feb;15(81):120-5. Review.

10.

Trial watch: Peptide vaccines in cancer therapy.

Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2012 Dec 1;1(9):1557-1576.

11.

Cytotoxicity of bacterial metabolic products, including listeriolysin O, on leukocyte targets.

Stachowiak R, Lyzniak M, Budziszewska BK, Roeske K, Bielecki J, Hoser G, Kawiak J.

J Biomed Biotechnol. 2012;2012:954375. doi: 10.1155/2012/954375. Epub 2012 Oct 3.

12.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

13.

Revisiting the role of T cells in tumor regression.

Bercovici N, Trautmann A.

Oncoimmunology. 2012 May 1;1(3):346-350.

14.

Spontaneous regression of pancreatic cancer: real or a misdiagnosis?

Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L.

World J Gastroenterol. 2012 Jun 21;18(23):2902-8. doi: 10.3748/wjg.v18.i23.2902. Review.

15.

Joint effects of febrile acute infection and an interferon-γ polymorphism on breast cancer risk.

Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie XM, Ren ZF.

PLoS One. 2012;7(5):e37275. doi: 10.1371/journal.pone.0037275. Epub 2012 May 18.

16.

Immunity over inability: The spontaneous regression of cancer.

Jessy T.

J Nat Sci Biol Med. 2011 Jan;2(1):43-9. doi: 10.4103/0976-9668.82318.

17.

Safety and clinical usage of newcastle disease virus in cancer therapy.

Lam HY, Yeap SK, Rasoli M, Omar AR, Yusoff K, Suraini AA, Alitheen NB.

J Biomed Biotechnol. 2011;2011:718710. doi: 10.1155/2011/718710. Epub 2011 Oct 26. Review.

18.

Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.

Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J.

Clin Cancer Res. 2010 Nov 1;16(21):5153-64. doi: 10.1158/1078-0432.CCR-10-0820. Epub 2010 Sep 20.

19.

Lipid A-mediated tolerance and cancer therapy.

Rockwell CE, Morrison DC, Qureshi N.

Adv Exp Med Biol. 2010;667:81-99. doi: 10.1007/978-1-4419-1603-7_8.

20.

Lipid A-mediated tolerance and cancer therapy.

Rockwell CE, Morrison DC, Qureshi N.

Adv Exp Med Biol. 2009;667:81-99. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk